Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (131-140 of 264) with videos related to

Pageof 27
Sort By:
Supportive Cancer Therapy|July 18, 2008
Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosisGiuseppe Curigliano, Mario Mandalà, Alberto Sbanotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerMarco Colleoni, Bernard F Cole, Giuseppe Viale, et al.
Clinical Breast Cancer|July 13, 2004
Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine featuresGiuseppe Curigliano, Rodrigo Rigo, Marco Colleoni, et al.
Clinical Breast Cancer|October 27, 2012
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcomeEmilia Montagna, Patrick Maisonneuve, Nicole Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapySalvatore Pece, Ivana Sestak, Francesca Montani, et al.
The Oncologist|July 3, 2016
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Anticancer Research|January 2, 2010
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancerAndrea Rocca, Giuseppe Cancello, Vincenzo Bagnardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatmentMarco Colleoni, Giuseppe Viale, David Zahrieh, et al.
Breast (Edinburgh, Scotland)|February 4, 2026
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer indexRuth M O'Regan, Yue Ren, Yi Zhang, et al.
Pageof 27

Showing results (131-140 of 264) with videos related to

Sort By:
Pageof 27
Supportive Cancer Therapy|July 18, 2008
Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosisGiuseppe Curigliano, Mario Mandalà, Alberto Sbanotto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerMarco Colleoni, Bernard F Cole, Giuseppe Viale, et al.
Clinical Breast Cancer|July 13, 2004
Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine featuresGiuseppe Curigliano, Rodrigo Rigo, Marco Colleoni, et al.
Clinical Breast Cancer|October 27, 2012
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcomeEmilia Montagna, Patrick Maisonneuve, Nicole Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2022
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapySalvatore Pece, Ivana Sestak, Francesca Montani, et al.
The Oncologist|July 3, 2016
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Anticancer Research|January 2, 2010
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancerAndrea Rocca, Giuseppe Cancello, Vincenzo Bagnardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatmentMarco Colleoni, Giuseppe Viale, David Zahrieh, et al.
Breast (Edinburgh, Scotland)|February 4, 2026
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer indexRuth M O'Regan, Yue Ren, Yi Zhang, et al.
Pageof 27